Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767192 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1UTS2RALDH1A1LMNA | |
| SCHEMBL6404263 | 0.79 | CTSK (0.50) | TAS1R3TAS1R1 | |
| SCHEMBL6771256 | 0.77 | CTSK (0.50) | TAS1R3TAS1R1UTS2R | |
| SCHEMBL6634574 | 0.76 | GRN (0.52) | — | |
| SCHEMBL4762088 | 0.75 | TAS1R3 (0.39) | TAS1R3TAS1R1MAPT | |
| SCHEMBL4762084 | 0.75 | TAS1R3 (0.39) | TAS1R3TAS1R1MAPT | |
| SCHEMBL4762152 | 0.74 | ROCK2 (0.39) | TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL4765041 | 0.74 | CTSK (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL701201 | 0.74 | TAS1R3 (0.73) | TAS1R3TAS1R1UTS2RALDH1A1LMNA | |
| SCHEMBL701200 | 0.74 | TAS1R3 (0.73) | TAS1R3TAS1R1UTS2RALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | TAS1R3 1703/4885TAS1R1 1423/4885UTS2R 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.